In antiphospholipid antibody (aPL)-positive patients, the risk of first or recurrent thrombosis increases with high-risk aPL profile, e.g., triple aPL-positivity, and with additional venous thromboembolism and cardiovascular disease risk factors; however, there are no biomarkers to predict future thrombosis. The gene discussed is FASLG; the disease is cardiovascular disorder.